Founders Financial Securities LLC Has $1.19 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Founders Financial Securities LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,039 shares of the medical research company’s stock after purchasing an additional 69 shares during the quarter. Founders Financial Securities LLC’s holdings in Thermo Fisher Scientific were worth $1,185,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of TMO. Gotham Asset Management LLC raised its position in Thermo Fisher Scientific by 47.5% in the 3rd quarter. Gotham Asset Management LLC now owns 2,654 shares of the medical research company’s stock valued at $1,343,000 after buying an additional 855 shares during the last quarter. Schonfeld Strategic Advisors LLC raised its position in Thermo Fisher Scientific by 54.3% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 12,107 shares of the medical research company’s stock valued at $6,128,000 after buying an additional 4,260 shares during the last quarter. Waverly Advisors LLC raised its position in Thermo Fisher Scientific by 6.2% in the 3rd quarter. Waverly Advisors LLC now owns 2,233 shares of the medical research company’s stock valued at $1,130,000 after buying an additional 131 shares during the last quarter. United Services Automobile Association acquired a new stake in Thermo Fisher Scientific in the 3rd quarter valued at approximately $5,300,000. Finally, First Business Financial Services Inc. acquired a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $210,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $70,238,340.48. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $567.28, for a total value of $5,672,800.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,238,340.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the sale, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. Insiders sold a total of 22,000 shares of company stock valued at $12,532,780 in the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on TMO. Deutsche Bank Aktiengesellschaft boosted their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. The Goldman Sachs Group boosted their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Jefferies Financial Group reaffirmed a “buy” rating and set a $650.00 price target (up previously from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. Robert W. Baird reduced their target price on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, April 25th. Finally, Citigroup initiated coverage on Thermo Fisher Scientific in a research note on Monday, March 18th. They set a “neutral” rating and a $620.00 target price for the company. Five research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $607.06.

Thermo Fisher Scientific Price Performance

NYSE TMO traded up $2.22 during midday trading on Friday, hitting $553.00. The company had a trading volume of 6,150,885 shares, compared to its average volume of 1,473,906. The company has a market capitalization of $211.09 billion, a PE ratio of 35.47, a P/E/G ratio of 2.57 and a beta of 0.79. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. The firm has a 50-day moving average price of $574.84 and a 200-day moving average price of $563.04. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The firm had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.28%. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.